Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT)
British Journal of Dermatology2013Vol. 170(2), pp. 425–434
Citations Over TimeTop 19% of 2013 papers
C. Paul, L. Puig, Knud Kragballe, Thomas A. Luger, Jo Lambert, Sergio Chimenti, Giampiero Girolomoni, Jean‐François Nicolas, E. Rizova, F. Lavie, S. Mistry, Paul Bergmans, Juliet N. Barker, Kristian Reich, on behalf of the TRANSIT Investigators, Zygmunt Adamski, G. F. Altomare, Maurizio Aricò, N. Aste, F. Aubin, Matthias Augustin, Fabio Ayala, H. Bachelez, E. Baran, J. Barker, I. Belinchón, P. Berbis, Maria Grazia Bernengo, D. Bessis, M. Beylot‐Barry, F.J. Bordas Orpinell, David Burden, Matilda Bylaitė, F. Cambazard, Sara Carazo, J.M. Carrascosa, G. Carretero, R. Cerio, S. Chimenti, Marc David, A.‐B. Duval‐Modeste, D.J. Eedy, L. Estebaranz, Paulo Filipe, I. Flytström, Eduardo Fonseca, R. Gamanya, Pierre‐Dominique Ghislain, Alberto Giannetti, G. Girolomoni, Dimitar Gospodinov, Christopher Griffiths, Jean‐Jacques Grob, G. Guillet, José Manuel Hernanz Hermosa, Matthias Hoffmann, Dimitrios Ioannidis, Arnd Jacobi, Gregor B. E. Jemec, Miroslava Kadurina, K. Kaszuba, A. Katsambas, Lajos Kemény, P. Kerkhof, K. Kragballe, N. Kuzmina, Katrina A. Lambert, Pablo Lázaro, T Lotti, TA Luger, Hagit Matz, P. Modiano, Rotraut Moessner, D. Moreno‐Ramírez, J.C. Moreno Jímenez, Nils‐Jørgen Mørk, U. Mrowietz, Ruth Murphy, Jean‐François Nicolas, Arjen Nikkels, Harley Francisco de Oliveira, Anthony D. Ormerod, J.‐P. Ortonne, Aurora Parodi, Rafael Pasternack, C. Paul, J. Péč, A. Peserico, Sandra Philipp, L. Piquet, P. Plantin, L. Puig, Kristian Reich, Éva Remenyik, Elisabeth Riedl, Martin Röcken, M.H.A. Rustin, Seppo Saari, P. Saïag, W. Salmhofer, D. Schadendorf, Michael Sebastian, Mária Šimaljaková, Jan C. Simon, Anna Spirén, J.F. Stalder, N.G. Stavrianeas, Michael Sticherling, T. Ternowitz, Diamant Thaçi, Bing Thio, D. Uhlig, Skaidra Valiukevičienė, F.J. Vanaclocha Sebastián, Gottfried Wozel
Abstract
Ustekinumab was well tolerated and effective in patients who had an inadequate response to methotrexate. Both transition strategies resulted in similar week 12 safety and efficacy outcomes.